Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2) - 12/08/11
St Louis, Missouri, and Dayton, Ohio
Abstract |
Recently, dermatologists have witnessed a revolution in our therapeutic armamentarium with the development of several novel biologic immunomodulators. Although psoriasis remains the only condition in dermatology for which the use of biologic immunomodulators has been approved by the Food and Drug Administration, these drugs have the potential to significantly impact the treatment of several inflammatory conditions in dermatology. This article includes a review of the mechanism of action, dosing, and side-effect profile, as well as a review of the current literature on off-label uses of the CD20-positive B-cell antagonist rituximab, the IgE antagonist omalizumab, the tumor necrosis factor-⍺ antagonists infliximab, etanercept, and adalimumab, and the T-cell response modifiers efalizumab and alefacept.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CHF, BP, DGA, DM, EAC, GA, GVHD, HACAs, HS, ICAM-1, IL, LBCLL, LFA-1, MMP, NLD, PCBCL, PG, PRP, PV, RA, SLE, SPD, TEN, TNF-⍺, WG
Plan
Funding sources: None. Disclosure: Dr Heffernan has been a paid investigator, lecturer and/or consultant for Abbott, Amgen, Biogen-IDEC, Centocor and Genentech. Drs Heffernan and Graves have been active in industry-sponsored research. Presented at the 63rd Annual Meeting of the American Academy of Dermatology, New Orleans, Louisianna, February 18-22, 2005. |
Vol 56 - N° 1
P. e55-e79 - janvier 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?